walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
about
Mechanisms of vancomycin resistance in Staphylococcus aureusMolecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureusEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRA mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Modulation of cell wall synthesis and susceptibility to vancomycin by the two-component system AirSR in Staphylococcus aureus NCTC8325.Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibilityAdditional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant Staphylococcus aureus strain MW2The Essential WalK Histidine Kinase and WalR Regulator Differentially Mediate Autolysis of Staphylococcus aureus RN4220Transcriptional Analysis and Subcellular Protein Localization Reveal Specific Features of the Essential WalKR System in Staphylococcus aureus.Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureusThe WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory responseDecreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory systemComprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus.Bacterial stress responses as determinants of antimicrobial resistance.Vancomycin therapeutics and monitoring: a contemporary approach.Genetic alterations responsible for reduced susceptibility to vancomycin in community-associated MRSA strains of ST72.Bacterial proteases, untapped antimicrobial drug targets.Involvement of WalK (VicK) phosphatase activity in setting WalR (VicR) response regulator phosphorylation level and limiting cross-talk in Streptococcus pneumoniae D39 cells.Activated ADI pathway: the initiator of intermediate vancomycin resistance in Staphylococcus aureus.Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental StrainPhenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis.Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia.A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA"Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus.β-Lactam resistance in methicillin-resistant Staphylococcus aureus USA300 is increased by inactivation of the ClpXP proteaseGeneration of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS.Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis.VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.Reduced vancomycin susceptibility in porcine ST9 MRSA isolates.Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.The role of thiol oxidative stress response in heat-induced protein aggregate formation during thermotolerance in Bacillus subtilis.Actinorhodin is a redox-active antibiotic with a complex mode of action against Gram-positive cells.
P2860
Q26829312-525539CB-63FD-416C-BFF4-6790816A8956Q28078930-6B7F2769-C110-44BD-A51B-4EE44A40A3BAQ28477900-F144983C-69E3-47C4-9271-1E6EF1F0543EQ30455758-3CC38761-ED95-4FD9-8033-4D2CE81B1468Q33644173-5D20E106-8751-43F9-9A7F-54D03A62222AQ33696380-522282CC-1F25-4717-AF84-3588ACFAD76FQ34130471-408C854B-0CEF-4924-967D-4C99CB15B2B4Q34596835-52C7DA87-2044-4283-935C-439A3312B6F2Q34632683-0CF956E6-2C17-477A-BB76-CB95A3373D7DQ34648042-CFD51A90-96EB-4ED8-A61D-F7F2C29777F3Q35105880-940391C5-CCA9-4889-B6CC-F8BE3062521BQ35687956-BA3664BA-FDA7-4CBC-81CD-0FE5A36DEE79Q35965021-2927868F-6AE2-4851-9358-18DCAAD3E848Q36153912-3BBBF86D-4796-4A68-BE42-EE3D7EA6C9C0Q36277416-3AB59582-D83A-4D6B-99B8-2AE1AF2D55BDQ36969754-A2EA7B60-D7D0-49CF-959D-C7556E0B6E08Q37190222-1CB75F75-C576-4226-B046-056B5FA83BB8Q37236231-2759D1A4-D09C-4DF8-9350-629D124102B9Q37335734-5E44E703-7B2C-496D-8C22-3E88F93362BFQ37575024-D9313873-1690-43CA-B4F6-10F1356E1CD2Q38012391-1A5A929E-CC32-41BE-8A5E-A035EA834F6BQ38062923-EDCABBE7-D28E-4B51-AA58-497FABE165B8Q38736105-26C3054E-1F6F-41C7-BF68-CBFE00097B77Q39023951-F8AEB9B8-8A55-4515-A590-69CE2307C026Q40204226-C81FA530-48A9-4E4E-96FF-79BE5A997D13Q40383094-7CF49B27-C015-4BCF-BA86-84852A2ECBD1Q40404574-475E8803-F7F9-47A9-AB42-38153C2680CBQ40896611-0C91535E-527E-48A5-A40F-87A0A681376EQ41087225-BA244D31-521D-4E72-946E-B2401C38A382Q41259277-02FB5C44-5155-40C7-98CC-62FA367BD844Q41570947-3723A394-35B4-450F-9234-54E081B02871Q41895801-C0C86F26-FB66-4066-A636-7A6087D9A4CDQ41953015-46252A84-16EE-4AE6-8491-0097FEE98751Q42202739-1484069C-AC82-4D58-914A-60C8A5E96C11Q42249678-3AED7F51-22E0-4C7A-BFF3-96CE7D1CE29BQ42358800-225E74F0-7912-4794-95CA-3F8829FC3785Q42905367-5218FD94-1FB2-417D-9A1F-2168DD66FE11Q46251747-85609754-A318-4544-AE70-0C783BFFAB72Q46355450-B4602F45-42DE-4856-9297-F1B35DA8C369Q47804224-9F1E8BB4-9EFF-43B4-BABB-3682B3831FCC
P2860
walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@en
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@nl
type
label
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@en
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@nl
prefLabel
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@en
walK and clpP mutations confer ...... lity in Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus
@en
P2093
Akira Komoto
Keiichi Hiramatsu
Longzhu Cui
Mitsutaka Shoji
Risa Iizuka
Tomomi Hishinuma
Yukiko Watanabe
P2860
P304
P356
10.1128/AAC.01563-10
P407
P50
P577
2011-05-31T00:00:00Z